...(technical difficulty) Steady progress in Biosimilars and ongoing traction in Research Services. Moving to discuss the financial highlights. For Q4, revenue from operations reached INR4,417 crore, reflecting a solid 15% year-on-year increase on a like-for-like basis and a 16% sequential growth. This growth was driven by a 46% year-on-year growth for Generics, 9% for Biosimilars and 11% for Research Services. Sequentially, all segments reported growth. Generics, particularly, was up 53%, while both Biosimilars and Research Services were up 8%. Core EBITDA for the quarter stood at INR1,363 crore, a 16% increase from last year with a healthy core operating margin of 31%. R&D investment for the quarter was INR231 crore, accounting for 7% of revenues with, of course, excluding Syngene. Reported EBITDA for Q4 was INR1,150 crore, which is a 60% year-on-year growth on a like-for-like basis. Profit before tax, excluding exceptional items, was INR466 crore, a strong 45% increase on a like-for-like...
